Mark Von Eisenburg

Mark Von Eisenburg supports clients by understanding translational research and science policy in a range of therapeutic areas.

He couples his training in age-related diseases and a focus on Alzheimer’s disease with a background in effective science communication, delivering digestible insights that help clients with market access strategies.

Prior to joining Avalere, Mark worked in biomedical research advocacy at the non-profit alliance Research!America, where he liaised with industry, professional society, patient group, and federal agency stakeholders across a suite of topic areas ranging from vaccine development to patent legislation, garnering deep knowledge of grass roots and grass tops methods to influence federal decision making. He previously interned with the Clinical Development and Medical Affairs team at Novartis, where he focused on pre-market oncology immunotherapy and cell therapy landscapes.

Mark holds a MS in integrative neuroscience from Georgetown University and a BS in neuroscience from Lafayette College.

Authored Content

Stakeholders in the COVID-19 pandemic response face regulatory and commercial uncertainties as emergency operations transition and market access of products face both emergency use and full licensure.